Regulation
Natera seeks Japan’s PMDA approval for Signatera test in MIBC
Natera submitted a regulatory application to Japan's PMDA (Pharmaceuticals and Medical Devices Agency) for approval of its Signatera test as a companion diagnostic for muscle-invasive bladder cancer (MIBC). The test is designed to detect circulating tumor DNA and inform treatment decisions in this patient population.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network